Chloroquine PhosphateThird Party Manufacturing in India

Chloroquine phosphate exerts its antimalarial effect through a mechanism that exploits the unique biology of the Plasmodium parasite within red blood cells. The drug is a lysosomotropic agent that accumulates preferentially in the acidic food vacuole of the malaria parasite. Within this vacuole, the parasite digests host hemoglobin to obtain essential amino acids for its growth and metabolism. This digestion process releases toxic heme, known as ferriprotoporphyrin IX, which the parasite normally detoxifies by polymerizing it into an insoluble crystalline pigment called hemozoin. Chloroquine interferes with this detoxification process by inhibiting the polymerization of heme into hemozoin. As a result, toxic heme accumulates within the food vacuole, causing oxidative damage to the parasite's membranes and ultimately leading to its death. The drug is active against the erythrocytic stages of Plasmodium species, which are responsible for the clinical symptoms of malaria. Chloroquine is a weak base that becomes protonated and trapped in the acidic vacuole, reaching concentrations hundreds of times higher than in the surrounding plasma. Beyond its antimalarial action, chloroquine also possesses immunomodulatory properties due to its ability to inhibit toll-like receptor signalling and reduce pro-inflammatory cytokine production, which has led to its use in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus. The drug also inhibits autophagy by raising lysosomal pH and blocking autophagosome-lysosome fusion.

Chloroquine phosphate is primarily indicated for the treatment and prophylaxis of malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum. It is specifically active against the erythrocytic forms of these parasites and remains the drug of choice in regions where chloroquine resistance has not emerged. For radical cure of P. vivax and P. ovale infections, chloroquine is used in conjunction with primaquine to eliminate the hypnozoite liver stages. Beyond malaria, chloroquine is used off-label in the treatment of rheumatoid arthritis, systemic lupus erythematosus, and porphyria cutanea tarda due to its immunomodulatory and anti-inflammatory properties. The drug has also been investigated for its antiviral and anticancer activities, including as an autophagy inhibitor in combination cancer therapy.

In the Indian pharmaceutical manufacturing landscape, chloroquine phosphate is a high-volume antimalarial molecule with decades of established production history. India is one of the world's largest manufacturers of chloroquine phosphate, supplying both domestic requirements and export markets across Africa, Southeast Asia, and Latin America where malaria remains endemic. The molecule is manufactured in multiple tablet strengths including 100mg, 160mg, 250mg, and 500mg, providing flexibility for both adult and pediatric dosing. The manufacturing process for chloroquine phosphate is well-established, with robust supply chains for raw materials and intermediates. Indian manufacturers have significant expertise in producing chloroquine phosphate to IP, USP, and BP pharmacopoeial standards simultaneously, enabling exports to regulated and semi-regulated markets alike. The drug's inclusion in the WHO Essential Medicines List and its continued role in national malaria control programmes ensure sustained demand for WHO-GMP certified chloroquine phosphate manufacturing in India.